✦ LIBER ✦

Author reply to recent improvement in the survival of patients with advanced nonsmall cell lung cancer enrolled in phase III trials of first-line, systemic chemotherapy

✍ Scribed by Katsuyuki Hotta; Yoshiro Fujiwara; Keitaro Matsuo

Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 38 KB
Volume: 110
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.23065

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Recent improvement in the survival of pa

Recent improvement in the survival of patients with advanced nonsmall cell lung cancer enrolled in phase III trials of first-line, systemic chemotherapy

✍ Alessandra Bearz; Diego Serraino; Lucia Fratino; Massimiliano Berretta; Umberto 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 38 KB 👁 3 views

A recent article by Hotta and colleagues 1 reports that survival of patients with nonsmall cell lung cancer (NSCLC) improved slowly over time from 1982 to 2002. Authors pooled together 121 phase 3 trials (42,768 patients overall),

Recent improvement in the survival of pa

Recent improvement in the survival of patients with advanced nonsmall cell lung cancer enrolled in phase III trials of first-line, systemic chemotherapy

✍ Katsuyuki Hotta; Yoshiro Fujiwara; Keitaro Matsuo; Takeshi Suzuki; Katsuyuki Kiu 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 264 KB 👁 3 views

Randomized phase 2 study of irinotecan p

Randomized phase 2 study of irinotecan plus cisplatin versus gemcitabine plus vinorelbine as first-line chemotherapy with second-line crossover in patients with advanced nonsmall cell lung cancer

✍ Ji-Youn Han; Dae Ho Lee; Jung Eun Song; Sung Young Lee; Hyae Young Kim; Heung Ta 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 145 KB 👁 1 views

Phase 2 trial of docetaxel and gefitinib

Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or older

✍ George R. Simon; Martine Extermann; Alberto Chiappori; Charles C. Williams; Mube 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 181 KB 👁 2 views

## Abstract ## BACKGROUND This is a phase 2 study of chemotherapy‐naive patients, 70 years of age or older, with nonsmall‐cell lung cancer (NSCLC) who were treated with docetaxel and gefitinib. The primary endpoint was response rate (RR). Secondary endpoints were overall survival (OS) and progress

Weekly docetaxel with either gemcitabine

Weekly docetaxel with either gemcitabine or vinorelbine as second-line treatment in patients with advanced nonsmall cell lung carcinoma : Phase II trials of the Minnie Pearl Cancer Research Network

✍ John D. Hainsworth; Howard A. Burris III; Frederic T. Billings III; James E. Bra 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 94 KB 👁 3 views

Phase II study of pemetrexed disodium, a

Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma : A study of the national cancer institute of Canada clinical trials group

✍ Frances A. Shepherd; Janet Dancey; Andrew Arnold; Alan Neville; James Rusthoven; 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 3 views

## Background: Pemetrexed disodium (alimta [eli lilly and company, indianapolis, in], ly231514, multitargeted antifolate) is a new multitargeted antifolate agent that inhibits multiple enzymes in the folate pathway. phase ii trials showed single-agent response rates of 16% and 23% in untreated pati